Fredun Pharmaceuticals Limited (BOM:539730)
India · Delayed Price · Currency is INR 906.70
+11.50 (1.28%)
At close: Jul 27, 2026
Fredun Pharmaceuticals Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Operating Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 326.21 | 197.39 | 156.23 | 108.07 | 63.35 |
Depreciation & Amortization | 81.87 | 49.14 | 37.42 | 27.65 | 21.33 |
Other Amortization | 0.6 | 1.26 | 0.54 | 0.44 | 0.24 |
Other Operating Activities | 399.75 | 303.08 | 187.99 | 155.43 | 79 |
Change in Accounts Receivable | 844.36 | -1,123 | -302.89 | 557.13 | -491.98 |
Change in Inventory | -299.16 | -648.91 | -248.74 | -1,037 | 211.14 |
Change in Accounts Payable | -571.83 | 818.41 | 36.04 | 107.26 | -113.44 |
Change in Income Taxes | 24.25 | 15.81 | 12.45 | -27.91 | -5.45 |
Change in Other Net Operating Assets | -687.03 | 220.57 | 116.57 | -35.53 | 212 |
Operating Cash Flow | 119.02 | -165.98 | -4.39 | -144.09 | -23.8 |
Operating Cash Flow Growth | - | - | - | - | - |
Investing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Capital Expenditures | -735.91 | -61.06 | -76.39 | -94.95 | -42.86 |
Sale of Property, Plant & Equipment | - | 1.12 | - | 0.9 | 1.43 |
Investment in Securities | - | -3.6 | - | - | - |
Investing Cash Flow | -735.91 | -63.54 | -76.39 | -94.05 | -41.43 |
Financing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Short-Term Debt Issued | 85.57 | 640.82 | 216.05 | 271.78 | 1.97 |
Long-Term Debt Issued | 466.97 | - | - | 68.89 | 129.29 |
Total Debt Issued | 552.54 | 640.82 | 216.05 | 340.67 | 131.25 |
Long-Term Debt Repaid | - | -24.45 | -26.42 | - | - |
Total Debt Repaid | - | -24.45 | -26.42 | - | - |
Net Debt Issued (Repaid) | 552.54 | 616.37 | 189.63 | 340.67 | 131.25 |
Issuance of Common Stock | 7.51 | 0.33 | - | - | - |
Other Financing Activities | 654.42 | -350.18 | -129.7 | -88.9 | -56.58 |
Financing Cash Flow | 1,214 | 266.51 | 59.93 | 251.77 | 74.67 |
Net Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Miscellaneous Cash Flow Adjustments | - | - | -0 | -0 | - |
Net Cash Flow | 597.58 | 36.99 | -20.85 | 13.63 | 9.44 |
Free Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -616.89 | -227.04 | -80.78 | -239.03 | -66.66 |
Free Cash Flow Growth | - | - | - | - | - |
Free Cash Flow Margin | -9.71% | -5.00% | -2.32% | -8.70% | -2.97% |
Free Cash Flow Per Share | -38.59 | -16.30 | -5.80 | -17.79 | -5.35 |
Levered Free Cash Flow | -1,066 | -551.85 | -269.38 | -445.24 | -337.49 |
Unlevered Free Cash Flow | -832.16 | -424.2 | -191.14 | -397.98 | -310.05 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash Interest Paid | 374.88 | 223.77 | 136.5 | 92.82 | 46.69 |
Change in Working Capital | -689.41 | -716.84 | -386.57 | -435.68 | -187.73 |